STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
Moberg Derma AB (OMX: MOB) has been granted 4 MSEK by Vinnova for the development of Limtop, an innovative formulation for the treatment of actinic keratosis, genital warts and basal cell cancer. The goal of the Vinnova funding is that small and medium-sized enterprises will increase their competitiveness and growth by investing in research and development and thus contribute to growth in Sweden.
Limtop is an innovative formulation aimed for the treatment of actinic keratosis, genital warts and basal cell cancer. The objective is a product with short treatment duration, an improved safety profile and an efficacy that is similar to or better than that of competing preparations. Limtop is based on a patent-pending formulation of a proven compound that results in a high and precise dose being transported into the skin. The company's preclinical results show that Limtop has a far greater capacity than existing preparations when it comes to transporting the active substance to the target tissue in the skin.
The grant of MSEK 4 will be used for development of the project that currently is in preclinical phase, with a goal to initiate clinical studies in the first half of 2012.
“We are very pleased that Limtop in hard competition was selected for financing. Vinnova's grant to Limtop is the largest in this round of the grant programme”, said Peter Wolpert, CEO of Moberg Derma.
Vinnova is planning to formalize decisions for projects grants no later than December 8th.
About this information
Moberg Derma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 12:00 am (CET) on November 15th, 2011.
About Moberg Derma
Moberg Derma AB (publ), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company’s products are based on proven compounds, which reduce time to market, development costs and risk. Moberg Derma’s product Nalox™/Emtrix®- for nail disorders - is the Nordic market leader and international launch is ongoing. The portfolio includes approved and launched products to projects in the preclinical and clinical phase. The company began operations at the Karolinska Institute in Stockholm in 2006. The share of Moberg Derma is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergderma.com
This information was brought to you by Cision http://www.cisionwire.com